Energy Fuels recently reported that it exceeded its 2025 uranium production, mined ore, and uranium concentrate sales ...

Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator ...

Adolescents with Human Immunodeficiency Virus (HIV) in Botswana, South Africa, Thailand, Uganda and the United States who ...

A controversial Hepatitis B vaccine safety trial will go on as planned in Africa, amid concerns over its ethics and design ...

Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%), and at 24 months, the survival rate was nearly 5 times higher in the ...

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...

A research team from the Yunnan Observatories of the Chinese Academy of Sciences (CAS), in collaboration with domestic and ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of ...